Whitehawk Q2 FY26 net loss narrows to $16.64 million

Reuters2026/08/06 12:06

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Whitehawk Therapeutics posted a Q2 net loss of USD 16.6 million, narrowing from USD 52.6 million a year earlier.
RD spending fell to USD 12.9 million from USD 48.8 million, on the prior-year quarter’s USD 38 million WuXi Biologics up-front license fee.
Cash, cash equivalents and short-term investments rose to USD 190 million at June 30 from USD 145.7 million at Dec. 31, 2025.
Phase 1 trials for HWK-007 and HWK-016 continued enrolling; HWK-206 Phase 1 initiation remains on track for Q3 2026.
CEO Dave Lennon said the company extended its cash runway into 2H 2028 following an upsized financing.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Whitehawk Therapeutics Inc. published the original content used to generate this news brief on August 06, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Whitehawk Q2 FY26 net loss narrows to $16.64 million

You may also like

Crypto prices